0001415889-20-000737.txt : 20200313
0001415889-20-000737.hdr.sgml : 20200313
20200313161015
ACCESSION NUMBER: 0001415889-20-000737
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200310
FILED AS OF DATE: 20200313
DATE AS OF CHANGE: 20200313
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BORKOWSKI EDWARD
CENTRAL INDEX KEY: 0001197542
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37853
FILM NUMBER: 20712745
MAIL ADDRESS:
STREET 1: 1500 CORPORATE DRIVE
STREET 2: SUITE 400
CITY: CANONSBURG
STATE: PA
ZIP: 15317
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AzurRx BioPharma, Inc.
CENTRAL INDEX KEY: 0001604191
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 760 PARKSIDE AVENUE
STREET 2: SUITE 304
CITY: BROOKLYN
STATE: NY
ZIP: 11226
BUSINESS PHONE: 646-699-7855
MAIL ADDRESS:
STREET 1: 760 PARKSIDE AVENUE
STREET 2: SUITE 304
CITY: BROOKLYN
STATE: NY
ZIP: 11226
FORMER COMPANY:
FORMER CONFORMED NAME: BioPharma d'Azur, Inc.
DATE OF NAME CHANGE: 20140331
4
1
form4-03132020_040301.xml
X0306
4
2020-03-10
0001604191
AzurRx BioPharma, Inc.
AZRX
0001197542
BORKOWSKI EDWARD
C/O AZURRX BIOPHARMA, INC.
760 PARKSIDE AVE SUITE 304
BROOKLYN
NY
11226
true
false
false
false
Common Stock
2020-03-10
4
A
0
14584
0.60
A
393710
D
Common Stock
2020-03-10
4
A
0
8414
1.04
A
402124
D
Common Stock
2020-03-10
4
A
0
1319
4.74
A
403443
D
Common Stock
2020-03-10
4
A
0
6330
4.74
A
409773
D
Common Stock
13680
I
By Spouse
Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending September 30, 2019.
Based on the stock price at September 30, 2019, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors.
Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending December 31, 2019.
Based on the stock price at December 31, 2019, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors.
Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending December 31, 2016.
Based on the stock price at December 31, 2016, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors.
Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors during 2016.
Based on the stock price at April 21, 2017, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors.
/s/ Edward J. Borkowski
2020-03-13